Impact of TECAR in Treatment of Rectus Diastasis

January 11, 2023 updated by: Doaa Rafat, Cairo University

Impact of TECAR Therapy in Treatment of Post-natal Rectus Diastasis

The study aim to evaluate the impact of TECAR treatment on rectus diastasis in postnatal women

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Radiofrequency (RF) is the emission of high frequency waves via an applicator. The transfer of electromagnetic energy stimulates targeted tissues. RF can be used in two ways: capacitive or resistive ( Kumarane etal.,2015) This has been shown to increase vascularization and reduce inflammation and swelling and to accelerate the healing process and provide pain relief( Duñabeitia et al., 2018). It is used to provide rapid pain relief for sport injuries and allows quicker recovery [Duñabeitia etal, 2018& Weber T, Kabelka2011). low back pain and traumatology and urology (Notarnicola etal, 2017). The capacitive mode (CET) concentrates the energy to target soft tissues containing electrolytes: muscles, vascular or lymphatic tissues. The resistive mode (RET) targets denser tissues containing more fat and fiber (such as bones, ligaments and tendons). High frequency waves penetrate deep into tissues and increase both exchanges and temperature and a recent study has demonstrated the effects of RF on the skin microcirculation and the intramuscular blood flow (Kumaraane et al., 2015). To date, no study has evaluated the impact of TECAR treatment on rectus diastasis in postnatal women This study will be carried out on 30 postnatal females suffering from diastasis recti more than 2.5 cm with bulged abdomen, they will be selected from out patient physical therapy clinic, kafr el sheikh university. Their age ranged from 25 - 35 years. Their body mass index (BMI) ranged from 25-35 kg/m2. All women delivered normally

Exclusion criteria:

Any participant was excluded if she had any disease that interferes with exercises (asthma), any skin disease or sensitivity that interferes with the application, any chest disease or cardiac disease or women had abdominal or surgery.

All participants will read an explanation of the experimental procedures and sign an informed consent that is approved by the Ethical committee Institutional Review Board, Faculty of Physical Therapy, kafr elsheikh University, Egypt This study will be a randomized, double-blind, pre test-post test crossover trial with control group. The randomization procedure will be performed by a simple drawing of lots (A or B) which determined whether participants would receive the TECAR therapy and abdominal exercises ( group A) and abdominal exercises only in (group B). The randomization procedure will be performed through a computer program (Microsoft Excel 2010) that created a random table of numbers in which each number corresponded to the group A or B. After that, participants will be allocated according to the corresponding number of their allocation code. A researcher will be conducted the drawing procedures without informing participants and evaluators, to determine which will be in group A or group B. Thus, both participants and evaluators will be blinded to the allocation of treatment.

Study group (Group A):

It was consisted of 15 post natal women who will performed weight reduction diet ( 1200 kcal/day) , TECAR application and selected abdominal exercises program that consists of static abdominal and posterior pelvic tilting

Control group(Group B):

It was consisted of 15 postnatal women who was performed weight reduction diet (1200 kcal/day) and selected abdominal exercises and posterior pelvic tilting exercises.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Tanta, Egypt
        • Kafrelshiesk university hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 35 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • postnatal females suffering from diastasis recti more than 2.5 cm with bulged abdomen,
  • Their age ranged from 25 - 35 years.
  • Their body mass index (BMI) ranged from 25-35 kg/m2.
  • All women delivered normally

Exclusion Criteria:

  • Any participant was excluded if she had any disease that interferes with exercises (asthma), any skin disease or sensitivity that interferes with the application, any chest disease or cardiac disease or women had abdominal surgery.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: TECAR application
Radiofrequency (RF) is the emission of high frequency waves via an applicator. The transfer of electromagnetic energy stimulates targeted tissues. RF can be used in two ways: capacitive or resistive The capacitive mode (CET) concentrates the energy to target soft tissues containing electrolytes: muscles, vascular or lymphatic tissues. The resistive mode (RET) targets denser tissues containing more fat and fiber (such as bones, ligaments and tendons). High frequency waves penetrate deep into tissues and increase both exchanges and temperature and a recent study has demonstrated the effects of RF on the skin microcirculation and the intramuscular blood flow
Active Comparator: selected abdominal exercises program
Radiofrequency (RF) is the emission of high frequency waves via an applicator. The transfer of electromagnetic energy stimulates targeted tissues. RF can be used in two ways: capacitive or resistive The capacitive mode (CET) concentrates the energy to target soft tissues containing electrolytes: muscles, vascular or lymphatic tissues. The resistive mode (RET) targets denser tissues containing more fat and fiber (such as bones, ligaments and tendons). High frequency waves penetrate deep into tissues and increase both exchanges and temperature and a recent study has demonstrated the effects of RF on the skin microcirculation and the intramuscular blood flow

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
rectus abdominis cross section area
Time Frame: 1 cycle (42 days)
1 cycle (42 days)
fat thickness
Time Frame: 1 cycle (42 days)
1 cycle (42 days)
intra-recti distance
Time Frame: 1 cycle (42 days)
1 cycle (42 days)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Eman A Elhosary, Professor, Assistant professor of physical therapy, Physical therapy faculty, Kafrelsheikh University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2022

Primary Completion (Actual)

August 31, 2022

Study Completion (Actual)

September 30, 2022

Study Registration Dates

First Submitted

March 10, 2022

First Submitted That Met QC Criteria

March 10, 2022

First Posted (Actual)

March 18, 2022

Study Record Updates

Last Update Posted (Actual)

January 12, 2023

Last Update Submitted That Met QC Criteria

January 11, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • PT/WH

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rectus Diastasis

Clinical Trials on TECAR application

Subscribe